Breaking News, Collaborations & Alliances

Boehringer Ingelheim, CDR-Life Partner to Develop CDR111 for Autoimmune Diseases

CDR111 is a trispecific M-gager, an antibody-based T-cell engager designed to selectively target and deplete B cells, with the goal of achieving immune system reset.

Author Image

By: Charlie Sternberg

Associate Editor

Boehringer Ingelheim and CDR-Life Inc. have announced a new global licensing agreement to develop CDR-Life’s antibody-based molecule CDR111 for autoimmune diseases. CDR111 is a trispecific M-gager, an antibody-based T-cell engager designed to selectively target and deplete B cells, with the goal of achieving immune system reset. Dysregulated B cells play a central role in driving many autoimmune and inflammatory conditions such as lupus, multiple sclerosis and certain forms of arthritis. Ther...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters